Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum]
Shiferaw D, Faruqi S. Ther Clin Risk Manag. 2019;15:1029–1040.Following a review of our paper post-publication, we found an error had been introduced during the typesetting process.On page 1029, the first sentence of the introduction section reads as “C...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-10-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Online Access: | https://www.dovepress.com/erratum-profile-of-tezacaftorivacaftor-combination-and-its-potent-peer-reviewed-article-TCRM |
| id |
doaj-5afe37f0728b4e64a8ea824f8117b0de |
|---|---|
| record_format |
Article |
| spelling |
doaj-5afe37f0728b4e64a8ea824f8117b0de2020-11-25T00:15:24ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2019-10-01Volume 151207120849082Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum]Shiferaw DFaruqi SShiferaw D, Faruqi S. Ther Clin Risk Manag. 2019;15:1029–1040.Following a review of our paper post-publication, we found an error had been introduced during the typesetting process.On page 1029, the first sentence of the introduction section reads as “Cystic fibrosis (CF) is a life-threatening genetic disease that affects approximately ct 380,000 people worldwide.1” This should read as “Cystic fibrosis (CF) is a life-threatening genetic disease that affects approximately 80,000 people worldwide.1”Read the original articlehttps://www.dovepress.com/erratum-profile-of-tezacaftorivacaftor-combination-and-its-potent-peer-reviewed-article-TCRM |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Shiferaw D Faruqi S |
| spellingShingle |
Shiferaw D Faruqi S Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum] Therapeutics and Clinical Risk Management |
| author_facet |
Shiferaw D Faruqi S |
| author_sort |
Shiferaw D |
| title |
Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum] |
| title_short |
Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum] |
| title_full |
Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum] |
| title_fullStr |
Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum] |
| title_full_unstemmed |
Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum] |
| title_sort |
profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis [erratum] |
| publisher |
Dove Medical Press |
| series |
Therapeutics and Clinical Risk Management |
| issn |
1178-203X |
| publishDate |
2019-10-01 |
| description |
Shiferaw D, Faruqi S. Ther Clin Risk Manag. 2019;15:1029–1040.Following a review of our paper post-publication, we found an error had been introduced during the typesetting process.On page 1029, the first sentence of the introduction section reads as “Cystic fibrosis (CF) is a life-threatening genetic disease that affects approximately ct 380,000 people worldwide.1” This should read as “Cystic fibrosis (CF) is a life-threatening genetic disease that affects approximately 80,000 people worldwide.1”Read the original article |
| url |
https://www.dovepress.com/erratum-profile-of-tezacaftorivacaftor-combination-and-its-potent-peer-reviewed-article-TCRM |
| work_keys_str_mv |
AT shiferawd profileoftezacaftorivacaftorcombinationanditspotentialinthetreatmentofcysticfibrosiserratum AT faruqis profileoftezacaftorivacaftorcombinationanditspotentialinthetreatmentofcysticfibrosiserratum |
| _version_ |
1716199541551661056 |